DELIVERING XENOTRANSPLANTATION
TO CLINICAL REALITY
XenoTherapeutics is a not-for-profit, clinical-stage regenerative medicine company
developing innovative cell and tissue-based research solutions.
Our FDA accepted pathogen screening and validated assays provide a robust regulatory pathway for clinical advancement of xenogeneic cells, tissues, and organs.
We accelerate the development, testing, training,
and commercialization of innovative, live biotherapeutic products that deliver on the
promise of regenerative medicine.
Our first clinical success is realSKIN™, closely followed by realNERVE™, and several more breakthrough solutions are on the horizon.
OUR MISSION
"To further advance the science of xenotransplantation through education, research, development, and clinical testing towards an eventual practical therapeutic use for the public benefit."
- Jon Adkins
CEO XenoTherapeutics Foundation
Patients are waiting on us
The availability of cells, tissues, and organs that are safe, widely available, and sufficiently immune-compatible to be transplanted into anyone is the promise of regenerative medicine. The question of where and how to source these precious therapeutic building blocks is complex and the topic of ongoing research.
Allotransplantation has inherent shortcomings, and for many patients, will never be sufficient to address the clinical needs of a vast number of diseases or conditions.
There is an urgent need for a reliable, ethical source, and recent advances in gene-editing capabilities combined with an expanded understanding of the genome have renewed the viability of an alternative.
Clinical xenotransplantation
has the potential to address this
unmet need on a large scale.
